ABC  Vol.7 No.2 , April 2017
Fc-Epsilon Receptor (CD23) Expressing Follicular Dendritic Cells as a Main Prognostic Factor in Follicular Lymphoma
Abstract: Fc-epsilon receptor (CD23)-expressing follicular dendritic cells is a main prognostic factor in follicular lymphoma. Falaleeva N. A., Osmanov E. A., Tupitsyn N. N. Federal State Budgetary Institute N. N. Blokhin Russian Cancer Research Center, Health Ministry of Russian Federation, Moscow, Russia SUMMARY Follicular dendritic cells, expressing FcεRII or CD23 (FcεRIIFDCs) as a component of non-tumor environment have been studied in 232 follicular lymphoma (FL) patients. FcεRIIFDCs were found in 87.5% of follicular lymphoma cases and were associated with a nodular pattern of tumor growth (p = 0.000), but not the cytological grade of lymphoma. There were no associations of FcεRIIFDC with clinical prognostic factors (FLIPI indices) or with bone marrow involvement in FL patients by histology. The presence of FcεRIIFDCs in tumor tissue was an independent prognostic factor according to treatment results, i.e. frequency of CR, duration of OS and PFS. Bone marrow involvement significantly worsened the prognosis in FcεRIIFDC-positive group of patients. We suggest a new prognostic index (FDC-IP) that allows biochemical identification of the following patient groups: FcεRIIFDC-positive patients without bone marrow involvement (good prognosis), FcεRIIF-DC-positive patients with bone marrow involvement (intermediate prognosis), FcεRIIFDC-negative patients (poor prognosis). These 3 groups significantly differ (p = 0.000) both in OS and in PFS. This is the first evidence of the possibility to assess tumor behavior and treatment results in FL according to lymphoma biochemical and other than clinical parameters.
Cite this paper: Falaleeva, N. , Osmanov, E. and Tupitsyn, N. (2017) Fc-Epsilon Receptor (CD23) Expressing Follicular Dendritic Cells as a Main Prognostic Factor in Follicular Lymphoma. Advances in Biological Chemistry, 7, 107-121. doi: 10.4236/abc.2017.72007.

[1]   Solal-Céligny, P., Roy, P., Colombat, P., White, J., Armitage, J.O., Arranz-Saez, R., Au, W.Y., Bellei, M., Brice, P., Caballero, D., Coiffier, B., Conde-Garcia, E., Doyen, C., Federico, M., Fisher, R.I., Garcia-Conde, J.F., Guglielmi, C., Hagenbeek, A., Haïoun, C., LeBlanc, M., Lister, A.T., Lopez-Guillermo, A., McLaughlin, P., Milpied, N., More,l P., Mounier, N., Proctor, S.J., Rohatiner, A., Smith, P., Soubeyran, P., Tilly, H., Vitolo, U., Zinzani, P.L., Zucca, E. and Montserrat, E. (2004) Follicular Lymphoma International Index. Blood, 104, 1258-1265.

[2]   Dave, S.S., Wright, G., Tan, B., Rosenwald, A., Gascoyne, R.D., Chan, W.C., Fisher, R.I., Braziel, R.M., Rimsza, L.M., Grogan, T.M., Miller, T.P., LeBlanc, M., Greiner, T.C., Weisenburger, D.D., Lynch, J.C., Vose, J., Armitage, J.O., Smeland, E.B., Kvaloy, S., Holte, H., Delabie, J., Connors, J.M., Lansdorp, P.M., Ouyang, Q., Lister, T.A., Davies, A.J., Norton, A.J., Muller-Hermelink, H.K., Ott, G., Campo, E., Montserrat, E., Wilson, W.H., Jaffe, E.S., Simon, R., Yang, L., Powell, J., Zhao, H., Goldschmidt, N., Chiorazzi, M. and Staudt, L.M. (2004) Prediction of Survival in Follicular Lymphoma Based on Molecular Features of Tumor-Infiltrating Immune Cells. The New England Journal of Medicine, 351, 2159-2169.

[3]   Swerdlow, S.H., Campo, E., Harris, N.L., et al. (2008) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th Edition, IARC Press, Lyon, 220-226.

[4]   Cheson, B.D., Horning, S.J., Coiffier, B., Shipp, M.A., Fisher, R.I., Connors, J.M., Lister, T.A., Vose, J., Grillo-López, A., Hagenbeek, A., Cabanillas, F., Klippensten, D., Hiddemann, W., Castellino, R., Harris, N.L., Armitage, J.O., Carter, W., Hoppe, R. and Canellos, G.P. (2000) Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin’s Lymphomas. NCI Sponsored International Working Group. Journal of Clinical Oncology, 17, 1244.

[5]   Maximow, A. (1927) Bindegewebe und blutbildende Gewebe. In: Von Mollendorf, W., Ed., Handbuch der normalen mikroskopischen Anatomie des Menschen, Springer, Berlin, Bd. II/I, 232-583.

[6]   Mitchell, J. (1965) Ultra Structure of the Antigen-Retaining Reticulum of Lymph Node Follicles as Shown by High-Resolution Autoradiography. Nature, 30, 500-502.

[7]   Muñoz-Fernández, R., Blanco, F.J., Frecha, C., Martín, F., Kimatrai, M., Abadía-Molina, A.C., García-Pacheco, J.M. and Olivares, E.G. (2006) Follicular Dendritic Cells Are Related to Bone Marrow Stromal Cell Progenitors and Myofibroblasts. The Journal of Immunology, 177, 280-289.

[8]   Kapasi, Z.F., Qin, D., Kerr, W.G., Kosco-Vilbois, M.H., Shultz, L.D., Tew, J.G. and Szakal, A.K. (1998) Follicular Dendritic Cell (FDC) Precursors in Primary Lymphoid Tissues. The Journal of Immunology, 160, 1078-1084.

[9]   Schriever, F. and Nadler, L.M. (1992) The Central Role of Follicular Dendritic Cells in Lymphoid Tissues. Advances in Immunology, 51, 243-284.

[10]   Aguzzi, A. and Krautler, R.J. (2010) Characterizing Follicular Dendritic Cells: A Progress Report. European Journal of Immunology, 40, 2134-2138.

[11]   Mackay, F. and Browning, J.L. (395) Turning off Follicular Dendritic Cells. Nature, 395, 26-27.

[12]   Hanayama, R., Tanaka, M., Miyasaka, K., Aozasa, K., Koike, M., Uchiyama, Y. and Nagata, S. (2004) Autoimmune Disease and Impaired Uptake of Apoptotic Cells in MFG-E8-Deficient Mice. Science, 304, 1147-1150.

[13]   Dreyling, M., Ghielmini, M., Marcus, R., Salles, G., Vitolo, U., Ladetto, M. and ESMO Guidelines Working Group (2014) Newly Diagnosed and Relapsed Follicular Lymphoma: ESMO Clinical Practical Guidelines for Diagnosis, Treatment and Follow up. Annals of Oncology, 25, 76-82.